33631-94-6

Usage

Uses

Used in Pharmaceutical Industry:
7-Acetamido-3,4-dihydro-2H-1,5-benzodioxepine is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to serve as a building block in the development of new drugs with potential therapeutic properties.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 7-Acetamido-3,4-dihydro-2H-1,5-benzodioxepine is utilized for the design and synthesis of novel compounds with potential biological activities. Its structural features make it a valuable component in the creation of molecules that can target specific biological pathways or receptors, contributing to the advancement of medical treatments.

InChI:InChI=1/C11H13NO3/c1-8(13)12-9-3-4-10-11(7-9)15-6-2-5-14-10/h3-4,7H,2,5-6H2,1H3,(H,12,13)

Upstream product

• 7216-18-4 3,4-dihydro-2H-benzo[b][1,4]dioxepine 
• 78288-94-5 3,4-dihydro-7-nitro-2H-1,5-benzodioxepine 
• 108-24-7 acetic anhydride 

Downstream Products

• 81864-61-1 7-acetamino-8-nitro-3,4-dihydro-2H-1,5-benzodioxepine 

Relevant academic research and scientific papers

Synthesis and crystal structure of 3, 4-dihydro-7-acetamido-2H-1,5-benzodioxepine

The synthesis of 3,4-dihydro-7-acetamido-2H-1,5-benzodioxepin III is achieved starting from 3,4-dihydro-7-nitro-benzodioxepin II. The new acetamid prepared is characterized by spectroscopic technics, IR; UV; 1H-NMR; 13C-NMR; mass spectrometry and by XR diffraction. A monocrystal from the product is selected and its crystal structure resolved. The solid crystallizes in orthorhombic system with space group Pcab. The crystal cohesion is assumed by hydrogen bonds and Vander-Waals interactions.

Imidazole derivatives

Tricyclic imidazole derivatives of the formula STR1 wherein R1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R2 is hydrogen or lower alkyl, R3 and R4, independently, are hydrogen or lower alkyl, A is a group of the formula STR2 m is the integer 2 or 3, R5, R6, R7 and R8, independently, are hydrogen or lower alkyl, and R9 is hydrogen and R10 is hydrogen or lower alkyl or R9 and R10 taken together are oxo, provided that at least one of R3 and R4 is lower alkyl when A is a group of the formula and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.